News

2022 management report: Revenue growth of 4% despite difficult conditions

The pfmmedical Group achieved revenue growth of around 4% in the 2022 financial year – despite many unforeseen circumstances that had a negative impact on revenue growth. For example, the war in Ukraine was not expected and people didn’t expect the coronavirus pandemic to have the influence it did. Despite the difficult conditions, the medical focus fields that steer business operations generated total revenue of EUR 131.7 million (previous year:...

pfmmedical invests in Lyra Medical to propel innovation in Pelvic Organ Prolapse treatment

pfm medical ag, an international medical technology specialist based in Cologne, invested in an Israeli company, Lyra Medical Ltd. in May 2023. In its prime area of focus, SURGERY, pfmmedical is a leading name in prolapse surgery, for anterior prolapse with or without the involvement of the apical compartment. With the aid of the SRS (SELF RETAINING SUPPORT) Implant and a titanised type 1a surgical mesh, patients can be treated using the...

pfmmedical mourns the death of its founder

Jürgen Wolter, founder of pfm medical ag, an international, second generation family-run medical technology company based in Cologne, passed away on 22 May 2023 at the age of 85. Jürgen Wolter leaves behind him a fulfilled life. After roughly 10 years of professional experience in an American corporation, he took the plunge into self-employment and founded what was then known as pfm Plastik für die Medizin GmbH alongside Peter Dahlhausen shortly...

Innovation: combining the advantages of meshes and surgical sutures

pfm medical ag is expanding its product portfolio to include DURAMESH™ Suturable Mesh. This innovative suturable mesh combines the advantages of mesh reconstruction with the accurate placement of surgical sutures for the first time. DURAMESH™ can replace surgical sutures when high forces need to be transferred. While meshes have the advantage of distributing forces over a large area and transferring the associated high forces, sutures have the...

Financial performance in 2021: Core business sees continued growth despite Covid restrictions

The 2021 reporting period was again dominated by the Covid-19 pandemic and the associated restrictions. This had varying effects on the individual companies of the pfmmedical group. While pfm medical tpm gmbh was severely impacted by the measures, revenue in China actually exceeded expectations by growing almost 40 per cent on the previous year. Overall revenue grew by EUR 7.9 m (+6.6 per cent), without accounting for the one-off additional...

Period

2022 management report: Revenue growth of 4% despite difficult conditions

pfmmedical invests in Lyra Medical to propel innovation in Pelvic Organ Prolapse treatment

pfmmedical mourns the death of its founder

Innovation: combining the advantages of meshes and surgical sutures

Financial performance in 2021: Core business sees continued growth despite Covid restrictions